Cardiovascular Safety of Empagliflozin Versus Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetes: Systematic Literature Review and Indirect Comparisons (vol 9, pg 1491, 2018)

被引：1
|
作者：
Balijepalli, Chakrapani [1 ]
Shirali, Rohan [1 ]
Kandaswamy, Prashanth [2 ]
Ustyugova, Anastasia [2 ]
Pfarr, Egon [2 ]
Lund, Soren S. [2 ]
Druyts, Eric [1 ]
机构：
[1] Precis Hlth Econ, Vancouver, BC, Canada
[2] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
来源：
DIABETES THERAPY | 2019年 / 10卷 / 01期
关键词：
D O I：
10.1007/s13300-018-0543-9
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The authors have updated Fig. 3 which was incorrectly published in the original publication.
引用
收藏
页码：325 / 326
页数：2
相关论文
共 50 条
  • [41] Are dipeptidyl peptidase-4 (DPP-4) inhibitors promising drugs in the therapy of type 1 diabetes mellitus? From the physiology to the recently raised concerns
    Firneisz, G.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2012, 42 : 43 - 43
  • [42] Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes: Meta-Analysis
    Park, Haesuk
    Park, Chanhyun
    Kim, Yoona
    Rascati, Karen L.
    ANNALS OF PHARMACOTHERAPY, 2012, 46 (11) : 1453 - 1469
  • [43] Heterogeneous Treatment Effects on Cardiovascular Diseases With Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas in Type 2 Diabetes Patients
    Yang, Chen-Yi
    Lin, Wei-Ann
    Su, Pei-Fang
    Li, Lun-Jie
    Yang, Chun-Ting
    Ou, Huang-Tz
    Kuo, Shihchen
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 (03) : 772 - 781
  • [44] Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis
    Goossen, K.
    Graeber, S.
    DIABETES OBESITY & METABOLISM, 2012, 14 (12): : 1061 - 1072
  • [45] Twelve-week efficacy and tolerability of sitagliptin, a Dipeptidyl Peptidase-4 (DPP-4) inhibitor, in Japanese patients with type 2 diabetes
    Nonaka, K.
    Kakikawa, T.
    Sato, A.
    Okuyama, K.
    Fujimoto, G.
    Hayashi, N.
    Suzuki, H.
    Hirayama, Y.
    Stein, P. P.
    DIABETOLOGIA, 2006, 49 : 25 - 26
  • [46] Effectiveness in clinical practice versus efficacy of dipeptidyl peptidase-4 inhibitors in clinical trials for type 2 diabetes: protocol for systematic review
    Batel-Marques, Francisco
    Pereira, Diogo
    Mendes, Diogo
    Alves, Carlos
    Penedones, Ana
    BMJ OPEN, 2019, 9 (09):
  • [47] Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment
    Thomas, Merlin C.
    Paldanius, Paivi M.
    Ayyagari, Rajeev
    Ong, Siew Hwa
    Groop, Per-Henrik
    DIABETES THERAPY, 2016, 7 (03) : 439 - 454
  • [48] Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment
    Merlin C. Thomas
    Päivi M. Paldánius
    Rajeev Ayyagari
    Siew Hwa Ong
    Per-Henrik Groop
    Diabetes Therapy, 2016, 7 : 439 - 454
  • [49] Review: In type 2 diabetes, adding dipeptidyl peptidase-4 inhibitors to sulphonylureas increases hypoglycemia
    Tanner, Michael
    ANNALS OF INTERNAL MEDICINE, 2016, 165 (04) : JC20 - JC20
  • [50] Dipeptidyl peptidase-4 inhibitors and cardiovascular events in patients with type 2 diabetes, without cardiovascular or renal disease
    Baksh, Sheriza N.
    Segal, Jodi B.
    McAdams-DeMarco, Mara
    Kalyani, Rita R.
    Alexander, G. Caleb
    Ehrhardt, Stephan
    PLOS ONE, 2020, 15 (10):
12345